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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
β-hydroxy β-methylbutyrate monohydrate (HMB) alone or in combination 
with α-ketoisocaproic acid (KIC) and reduction of muscle tissue damage 
during exercise (ID 1577, 1584), increase in lean body mass (ID 1579, 1582, 
1583), increase in muscle strength (ID 1578, 1583, 1587), increase in 
endurance performance (ID 1580, 1581), skeletal muscle tissue repair 
(ID 1586) and faster recovery from muscle fatigue after exercise (ID 1576, 
1585) pursuant to Article 13(1) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to β-hydroxy β-methylbutyrate monohydrate (HMB) alone or in combination with 
α-ketoisocaproic acid (KIC) and reduction of muscle tissue damage during exercise, increase in lean 
body mass, increase in muscle strength, increase in endurance performance, skeletal muscle tissue 
repair and faster recovery from muscle fatigue after exercise. The scientific substantiation is based on 
the information provided by the Member States in the consolidated list of Article 13 health claims and 
references that EFSA has received from Member States or directly from stakeholders. 
The food constituent that is the subject of the health claims is HMB, either alone or in combination 
with KIC. The Panel considers that HMB either alone or in combination with KIC is sufficiently 
characterised.  
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-2313, EFSA-Q-2008-2314, EFSA-Q-2008-2315, 
EFSA-Q-2008-2316, EFSA-Q-2008-2317, EFSA-Q-2008-2318, EFSA-Q-2008-2319, EFSA-Q-2008-2320, EFSA-Q-
2008-2321, EFSA-Q-2008-2322, EFSA-Q-2008-2323, EFSA-Q-2008-2324, adopted on 08 April 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank for the preparatory work on this scientific opinion: The members of the 
Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub-Working Group 
on Weight Management/Satiety/Glucose and Insulin Control/Physical Performance: Kees de Graaf, Joanne Harrold, Mette 
Hansen, Mette Kristensen, Anders Sjödin and Inge Tetens. 
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Reduction of muscle tissue damage during exercise 
The claimed effects are “minimize muscle protein breakdown” and “HMB and exercise induced 
muscle breakdown”. The target population is assumed to be adults performing resistance exercise. In 
the context of the proposed wordings and the references provided, the Panel assumes that the claimed 
effects relate to the reduction of damage to muscle tissue during exercise. The Panel considers that 
reduction of muscle tissue damage during exercise is a beneficial physiological effect. 
In weighing the evidence, the Panel took into account that although one small randomised controlled 
trial with methodological limitations reported a significant effect of HMB in combination with KIC 
on surrogate measures of muscle damage during resistance training, one meta-analysis of randomised 
controlled trials, which included five studies and eight intervention arms, did not show an effect of 
HMB supplementation on muscle tissue damage during exercise. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of HMB, either alone or in combination with KIC, and 
reduction of muscle tissue damage during exercise. 
Increase in lean body mass 
The claimed effects are “increasing mass”, “HMB and lean body mass”, and “HMB and training 
adaptations”. The target population is assumed to be physically active individuals in the general 
population. In the context of the proposed wordings, the Panel assumes that the claimed effects refer 
to an increase in lean body mass relative to body fat mass. The Panel considers that an increase in 
lean body mass is a beneficial physiological effect. 
In weighing the evidence, the Panel took into account that a meta-analysis of ten randomised 
controlled trials, and one additional randomised controlled trial not included in the meta-analysis, did 
not show a significant effect of HMB consumption on lean body mass during training compared to 
placebo.  
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of HMB, either alone or in combination with KIC, and 
increase in lean body mass. 
Increase in muscle strength 
The claimed effects are “increasing strength”, “HMB and training adaptations”, and “HMB and 
changes in muscle strength during training”. The target population is assumed to be adults performing 
resistance training to improve muscle strength. In the context of the proposed wordings, the Panel 
assumes that the claimed effects refer to an increase in muscle strength. The Panel considers that an 
increase in muscle strength is a beneficial physiological effect.  
In weighing the evidence, the Panel took into account that the results from a meta-analysis of 
randomised controlled trials with respect to the effect of HMB consumption on muscle strength are 
inconsistent, that no significant effect of HMB consumption on muscle strength was shown in the 
target population for the claim, and that no evidence for a mechanism by which HMB could exert the 
claimed effect was provided.  
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of HMB, either alone or in combination with KIC, and 
increase in muscle strength.  
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Increase in endurance performance 
The claimed effects are “increasing exercise lactate threshold and VO2 peak”, and “HMB and aerobic 
metabolism”. The target population is assumed to be adults performing endurance exercise. In the 
context of the proposed wordings and clarifications provided by Member States, the Panel assumes 
that the claimed effects refer to an increase in endurance performance. The Panel considers that 
increase in endurance performance is a beneficial physiological effect. 
No references which addressed the effects of HMB supplementation in humans on measures of 
endurance performance, and from which conclusions could be drawn for the scientific substantiation 
of the claim, were provided.   
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of HMB, either alone or in combination with KIC, and 
increase in endurance performance. 
Skeletal muscle tissue repair  
The claimed effect is “HMB and normal muscle repair”. The target population is assumed to be adults 
performing resistance exercise. In the context of the proposed wordings, the Panel assumes that the 
claimed effect refers to the rebuilding of structural protein within skeletal muscle tissue after exercise 
which has caused muscle damage. The Panel considers that skeletal muscle tissue repair is a 
beneficial physiological effect. 
No references which addressed the effects of HMB supplementation in humans on measures of 
skeletal muscle tissue repair were provided.  
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of HMB, either alone or in combination with KIC, and 
skeletal muscle tissue repair. 
Faster recovery from muscle fatigue after exercise 
The claimed effects are “sport exercise recovery” and “HMB and muscle recovery after training”. The 
target population is assumed to be adults performing strenuous exercise. The Panel assumes that the 
claimed effects refer to muscle fatigue recovery after exercise. The Panel considers that faster 
recovery from muscle fatigue after exercise is a beneficial physiological effect. 
In weighing the evidence, the Panel took into account that the one human intervention study provided 
from which conclusions could be drawn for the scientific substantiation of the claim did not show an 
effect of HMB on faster recovery from muscle fatigue after exercise. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of HMB, either alone or in combination with KIC, and 
faster recovery from muscle fatigue after exercise. 
KEY WORDS 
β-hydroxy β-methylbutyrate monohydrate, α-ketoisocaproic acid, HMB, KIC, muscle, strength, endurance, 
repair, exercise, health claims.  
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation EC (No) 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C.  
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claims is “HMB (β-hydroxy β-methylbutyrate 
monohydrate)” and “HMB and HMB/KIC combinations”.  
From the information provided, the Panel assumes that the food constituent that is the subject of the 
health claims is HMB, either alone or in combination with α-ketoisocaproic acid (KIC).  
β-Hydroxy β-methylbutyric acid (HMB), or β-hydroxy β-methylbutyrate, is a metabolite of the amino 
acid leucine. HMB can be synthesised in the human body (about 0.2-0.4 g/day) and is usually 
available in supplements as a calcium salt. KIC is also an intermediate metabolite of leucine. Both 
HMB and KIC can be measured in food by established methods.  
The Panel considers that the food constituent, either HMB alone or in combination with KIC, which is 
the subject of the health claims, is sufficiently characterised.  
2. Relevance of the claimed effect to human health 
2.1. Reduction of muscle tissue damage during exercise (ID 1577, 1584) 
The claimed effects are “minimize muscle protein breakdown” and “HMB and exercise induced 
muscle breakdown”. The Panel assumes that the target population is adults performing resistance 
exercise. 
In the context of the proposed wordings and the references provided, the Panel assumes that the 
claimed effects relate to the reduction of damage to muscle tissue during exercise.  
The Panel considers that reduction of muscle tissue damage during exercise is a beneficial 
physiological effect. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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2.2. Increase in lean body mass (ID 1579, 1582, 1583) 
The claimed effects are “increasing mass”, “HMB and lean body mass”, and “HMB and training 
adaptations”. The Panel assumes that the target population is physically active individuals in the 
general population. 
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to an 
increase in lean body mass relative to body fat mass.  
The Panel considers that an increase in lean body mass is a beneficial physiological effect. 
2.3. Increase in muscle strength (ID 1578, 1583, 1587) 
The claimed effects are “increasing strength”, “HMB and training adaptations”, and “HMB and 
changes in muscle strength during training”. The Panel assumes that the target population is adults 
performing resistance training to improve muscle strength. 
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to an 
increase in muscle strength. In sports, muscle strength is sometimes a limiting factor for physical 
performance.  
The Panel considers that an increase in muscle strength is a beneficial physiological effect.  
2.4. Increase in endurance performance (ID 1580, 1581)  
The claimed effects are “increasing exercise lactate threshold and VO2 peak”, and “HMB and aerobic 
metabolism”. The Panel assumes that the target population is adults performing endurance exercise. 
In the context of the proposed wordings and clarifications provided by Member States, the Panel 
assumes that the claimed effects refer to an increase in endurance performance. Endurance 
performance relates to the ability to complete certain tasks with higher intensity, faster, or with a 
higher power output when performing long-term exercise. 
The Panel considers that an increase in endurance performance is a beneficial physiological effect. 
2.5. Skeletal muscle tissue repair (ID 1586) 
The claimed effect is “HMB and normal muscle repair”. The Panel assumes that the target population 
is adults performing resistance exercise.  
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to the 
rebuilding of structural protein within skeletal muscle tissue after exercise which has caused muscle 
damage.  
The Panel considers that skeletal muscle tissue repair is a beneficial physiological effect. 
2.6. Faster recovery from muscle fatigue after exercise (ID 1576, 1585) 
The claimed effects are “sport exercise recovery” and “HMB and muscle recovery after training”. The 
Panel assumes that the target population is adults performing strenuous exercise. 
The Panel assumes that the claimed effects refer to muscle fatigue recovery after exercise.  
β-Hydroxy β-methylbutyrate monohydrate (HMB) alone or in combination with 
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Fatigue can be defined as the loss of peak force or power output. Therefore, muscle fatigue recovery 
can be defined as the regain of maximal muscle strength or muscle power after performance of 
strenuous exercise which has induced muscle fatigue. 
The Panel considers that faster recovery from muscle fatigue after exercise is a beneficial 
physiological effect. 
3. Scientific substantiation of the claimed effect 
Some of the references provided for the scientific substantiation of the claims evaluated in this 
opinion were studies and narrative reviews which addressed the effects of HMB on outcomes (e.g. fat 
metabolism, hepatic and renal function, and cardiovascular system function) unrelated to the claimed 
effects, or which did not include original data for the scientific substantiation of the claim. The Panel 
considers that no conclusions can be drawn from these references for the scientific substantiation of 
the claims.  
A meta-analysis of randomised controlled trials (RCTs) (Rowlands and Thomson, 2009) on the 
effects of HMB on outcomes of body composition, muscle strength and muscle damage included the 
majority of the publications submitted, and from which conclusions could be drawn for the scientific 
substantiation of the claims. The meta-analysis included 10 RCTs with a parallel design and one RCT 
with a cross-over design (with one-week washout between interventions). In these trials 
(17 intervention arms), 12 intervention arms assessed measures of muscle strength, 16 intervention 
arms provided body composition estimates, and eight intervention arms reported on muscle damage 
assessed by creatine kinase (CK) concentrations. The meta-analysis comprised 394 trained (n=259) 
and untrained (n=135) weight lifters on resistance training for 5±6 h/week (range 3-20 h/week), and 
interventions lasting 3-9 weeks. The HMB dose in all but two studies was 3.0 g/day (range 
1.5-6.0 g/day). 
Another meta-analysis of RCTs on the effects of HMB supplementation on lean body mass and 
strength during resistance training, and which included a literature search from 1967 to 2001, was 
provided (Nissen and Sharp, 2003). This meta-analysis included only seven RCTs on HMB (and 9 
intervention arms), all of which were included in the meta-analysis by Rowlands and Thomson 
(2009). The Panel considers that this meta-analysis does not provide evidence for the scientific 
substantiation of the claims in addition to that of the meta-analysis by Rowlands and Thomson (2009). 
3.1. Reduction of muscle tissue damage during exercise (ID 1577, 1584) 
In the meta-analysis by Rowlands and Thomson (2009), a total of five studies, including eight effect 
estimates, addressed the effects of HMB supplementation on muscle damage during resistance 
training by means of blood concentrations of CK as a marker of muscle membrane damage (Jówko et 
al., 2001; Kreider et al., 1999; Kreider et al., 2000; Nissen et al., 1996; Panton et al., 2000). All 
intervention arms used doses of HMB of 3.0 g/day except one (i.e. 1.5 g/day). Five arms used 
untrained subjects whereas three used trained subjects. All subjects were young males (87 in the 
intervention and 88 in the control group). No significant effect of HMB consumption on CK 
concentrations was observed compared to placebo. 
Two studies, which addressed the effect of HMB on measures of muscle damage, and which were not 
included in the meta-analysis, were also provided (Knitter et al., 2000; van Someren et al., 2005). 
In the cross-over RCT by van Someren et al. (2005), six non resistance trained male subjects 
performed an exercise protocol designed to induce muscle damage on the dominant or non-dominant 
arm on two separate occasions. Subjects consumed HMB in combination with KIC (3.0 g HMB and 
0.3 g KIC, daily) and placebo (3.0 g corn flour) given in three equal doses during the day, for 14 days 
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prior to exercise. The order of the interventions was randomised. One repetition maximum (1RM), 
plasma CK activity, delayed onset muscle soreness (DOMS), limb girth, and range of motion (ROM) 
were determined pre-exercise, at 1 h, 24 h, 48 h, and 72 h post-exercise. The Panel notes that the 
primary outcome of the study was not identified, that no power calculations were performed, and that 
no control for multiplicity of analyses was applied. HMB and KIC supplementation significantly 
attenuated the CK response compared to placebo (p<0.05). The Panel considers that limited 
conclusions can be drawn from this study for the scientific substantiation of the claim.  
In the RCT by Knitter et al. (2000), subjects (n=16, 8 males) were paired according to their 2-mile run 
times and past running experience. Each pair was randomly assigned a treatment of either HMB 
(3.0 g/day) or placebo (rice maltodextrin). After six weeks of daily training and supplementation, all 
subjects participated in a prolonged run (20-km course). CK and lactate dehydrogenase (LDH) 
activities were measured before and after the run to assess muscle damage. Three subjects from the 
placebo group withdrew from the study, and data analyses were performed in the sample of 
completers only (n=5 placebo, n=8 HMB). Power calculations were not performed. The Panel notes 
that all drop outs belonged to the placebo group, and that drop outs (and therefore the breaking of the 
initial group matching by training status) were not taken into account in data analysis. The Panel 
considers that no conclusions can be drawn from this study for the scientific substantiation of the 
claim.  
In weighing the evidence, the Panel took into account that although one small RCT with 
methodological limitations reported a significant effect of HMB in combination with KIC on 
surrogate measures of muscle damage during resistance training, one meta-analysis of RCTs which 
included five studies and eight intervention arms did not show an effect of HMB supplementation on 
muscle tissue damage during exercise. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of HMB, either alone or in combination with KIC, and reduction of muscle tissue 
damage during exercise.  
3.2. Increase in lean body mass (ID 1579, 1582, 1583) 
Ten of the 11 RCTs considered in the meta-analysis by Rowlands and Thomson (2009), and which 
included 16 intervention arms, assessed the effects of HMB supplementation on lean body mass and 
reported size estimates. Body composition was assessed by skin fold thickness in three trials 
(Gallagher et al., 2000; Panton et al., 2000; Ransone et al., 2003), by bioelectrical impedance analysis 
(BIA) in two trials (Jówko et al., 2001; Thomson et al., 2009), by total body electrical conductivity 
(TOBEC) in one trial (Nissen et al., 1996), and by dual-energy x-ray absorptiometry (DXA) in four 
trials (Kreider et al., 1999; Kreider et al., 2000; Slater et al., 2001; Vukovich et al., 2001). No 
significant effect of HMB on changes in fat-free mass was observed in either trained (mean=0.8 %, 
90 % CI -0.4 % to 2 %) or untrained (mean=0.9 %, 90 % CI -0.2 % to 2 %) subjects. The Panel notes 
that skin fold thickness, BIA and TOBEC may not be as reliable methods as DXA to assess changes 
in body composition in short-term intervention studies. The Panel also notes that none of the studies 
which assessed changes in lean body mass using DXA found a significant effect of HMB compared to 
placebo.  
An additional RCT, which assessed the effects of HMB supplementation on lean body mass and 
which was not included in the meta-analysis by Rowlands and Thomson (2009), was provided 
(Lamboley et al., 2007). College students were randomly assigned to consume either HMB (3 g/day; 
n=8, 4 men) or placebo (placebo not reported; n=8, 4 men) for a 5-week supplementation period 
during which they underwent interval training three times a week on a treadmill. Body composition 
was assessed by DXA before and after training. No significant differences between groups were 
observed with respect to changes in body composition, including lean body mass.  
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In weighing the evidence, the Panel took into account that a meta-analysis of ten RCTs, and one 
additional RCT not included in the meta-analysis, did not show a significant effect of HMB 
consumption on lean body mass during training compared to placebo.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of HMB, either alone or in combination with KIC, and increase in lean body mass.  
3.3. Increase in muscle strength (ID 1578, 1583, 1587) 
Ten of the 11 RCTs considered in the meta-analysis by Rowlands and Thomson (2009), and which 
included 14 intervention arms, assessed the effects of HMB supplementation on measures of overall, 
upper and lower body muscular strength. The strength measure used was 1RM in seven studies 
(Gallagher et al., 2000; Jówko et al., 2001; Kreider et al., 1999; Panton et al., 2000; Ransone et al., 
2003; Thomson et al., 2009; Vukovich and Dreifort, 2001), 3RM in two studies (O'Connor and 
Crowe, 2003; Slater et al., 2001) and a strength index, calculated as the average weight lifted to 
failure (4-6 repetitions) during three sets multiplied by the number of repetitions the weight was 
lifted, in one study (Nissen et al., 1996). There was a small but statistically significant effect of HMB 
on overall average muscle strength when all studies and subjects were combined (mean=3.7 %, 
90 % CI 1.3 % to 6.1 %). This effect was due to the significant changes observed in untrained 
individuals (mean=6.6 %, 90 % CI 0.9 % to 2.3 %), particularly in lower body strength (mean=9.9 %, 
90 % CI 4 % to 15.8 %). No significant changes in muscle strength were observed in the upper body 
for untrained lifters, or for trained lifters in overall, upper body or lower body strength. No 
explanation for the differential effects of HMB supplementation observed in trained vs. untrained 
subjects, or in upper vs. lower body strength in untrained subjects, has been provided. The Panel notes 
that the results from this meta-analysis with respect to the effect of HMB consumption on muscle 
strength are inconsistent. The Panel also notes that no significant effect of HMB consumption on 
muscle strength was shown in the target population (i.e. active individuals who are performing 
resistance training to improve muscle strength) for the claim.  
An effect of HMB on protein turnover leading to an increase in lean body mass, and an effect of HMB 
on the reduction of skeletal muscle damage during exercise, have been hypothesised as the 
mechanisms by which HBM could improve muscle strength. However, the Panel notes that no 
evidence has been provided for any of these mechanisms (see sections 3.1 and 3.2).  
In weighing the evidence, the Panel took into account that the results from a meta-analysis of RCTs 
with respect to the effect of HMB consumption on muscle strength are inconsistent, that no significant 
effect of HMB consumption on muscle strength was shown in the target population for the claim, and 
that no evidence for a mechanism by which HMB could exert the claimed effect was provided.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of HMB, either alone or in combination with KIC, and increase in muscle strength.  
3.4. Increase in endurance performance (ID 1580, 1581)  
Two of the human intervention studies provided assessed the effects of HMB on measures of maximal 
oxygen consumption (VO2 max), on ventilatory threshold or on the onset of blood lactate 
accumulation (Lamboley et al., 2007; Vukovich and Dreifort, 2001), but the studies did not include 
any measure of endurance performance. The Panel considers that no conclusions can be drawn from 
these references for the scientific substantiation of the claim.  
In a RCT by O’Connor and Crowe (2003), the effects of a 6-week oral supplementation with HMB 
(3.0 g/day) vs. a mixture of HMB and creatine monohydrate (3.0 g/day HMB plus 3.0 g/day creatine) 
on aerobic and anaerobic capacity, peak power and total work during a cycling test in highly trained 
β-Hydroxy β-methylbutyrate monohydrate (HMB) alone or in combination with 
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rugby players were assessed. The control group was self-selected and received no treatment. The 
Panel notes that randomisation and blinding were only applied to subjects assigned to the two 
intervention groups. No statistically significant effect of HMB on peak power or total work was 
observed compared to the control group. The Panel notes the important limitations of the study 
design, and considers that no conclusions can be drawn for the scientific substantiation of the claim.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of HMB, either alone or in combination with KIC, and increase in endurance 
performance.  
3.5. Skeletal muscle tissue repair (ID 1586) 
No references addressing the effects of HMB supplementation in humans on measures of skeletal 
muscle tissue repair were provided.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of HMB, either alone or in combination with KIC, and skeletal muscle tissue repair. 
3.6. Faster recovery from muscle fatigue after exercise (ID 1576, 1585) 
In the RCT by Paddon-Jones et al. (2001), non resistance trained male subjects were randomly 
assigned to consume 40 mg/kg body weight per day of HMB (n=8) or placebo (maltodextrin calcium 
carbonate, n=9) for six days prior to a bout of 24 maximal isokinetic eccentric contractions of the 
elbow flexors, and this protocol continued throughout post testing. Muscle soreness, upper arm girth, 
and torque measures were assessed pre-exercise, 15 min post-exercise, and 1, 2, 3, 4, 7, and 10 days 
post-exercise. Power calculations were not performed. No pre-test differences between HMB and 
control groups were observed, and both groups performed a similar amount of eccentric work during 
the main eccentric exercise bout. HMB supplementation had no effect on swelling, muscle soreness, 
or torque following the damaging eccentric exercise bout. The Panel notes that this study does not 
show an effect of HMB on faster recovery from muscle fatigue after exercise.  
No other references which addressed the effects of HMB supplementation in humans on measures of 
muscle fatigue recovery after exercise were provided. 
In weighing the evidence, the Panel took into account that the one human intervention study provided 
from which conclusions could be drawn for the scientific substantiation of the claim did not show an 
effect of HMB on faster recovery from muscle fatigue after exercise. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of HMB, either alone or in combination with KIC, and faster recovery from muscle 
fatigue after exercise. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, HMB either alone or in combination with KIC, which is the subject of 
the health claims, is sufficiently characterised.  
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Reduction of muscle tissue damage during exercise (ID 1577, 1584) 
 The claimed effects are “minimize muscle protein breakdown” and “HMB and exercise 
induced muscle breakdown”. The target population is adults performing resistance exercise. 
Reduction of muscle tissue damage during exercise is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of HMB, 
either alone or in combination with KIC, and reduction of muscle tissue damage during 
exercise. 
Increase in lean body mass (ID 1579, 1582, 1583) 
 The claimed effects are “increasing mass”, “HMB and lean body mass”, and “HMB and 
training adaptations”. The target population is assumed to be physically active individuals in 
the general population. Increase in lean body mass is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of HMB, 
either alone or in combination with KIC, and increase in lean body mass. 
Increase in muscle strength (ID 1578, 1583, 1587) 
 The claimed effects are “increasing strength”, “HMB and training adaptations”, and “HMB 
and changes in muscle strength during training”. The target population is assumed to be adults 
performing resistance training to improve muscle strength. Increase in muscle strength is a 
beneficial physiological effect.  
 A cause and effect relationship has not been established between the consumption of HMB, 
either alone or in combination with KIC, and increase in muscle strength.  
Increase in endurance performance (ID 1580, 1581) 
 The claimed effects are “increasing exercise lactate threshold and VO2 peak”, and “HMB and 
aerobic metabolism”. The target population is assumed to be adults performing endurance 
exercise. An increase in endurance performance is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of HMB, 
either alone or in combination with KIC, and increase in endurance performance. 
Skeletal muscle tissue repair (ID 1586) 
 The claimed effect is “HMB and normal muscle repair”. The target population is assumed to 
be adults performing resistance exercise. Skeletal muscle tissue repair is a beneficial 
physiological effect. 
 A cause and effect relationship has not been established between the consumption of HMB, 
either alone or in combination with KIC, and skeletal muscle tissue repair. 
Faster recovery from muscle fatigue after exercise (ID 1576, 1585) 
 The claimed effects are “sport exercise recovery” and “HMB and muscle recovery after 
training”. The target population is assumed to be adults performing strenuous exercise. It is 
assumed that the claimed effects refer to muscle fatigue recovery after exercise. Faster 
recovery from muscle fatigue after exercise is a beneficial physiological effect. 
β-Hydroxy β-methylbutyrate monohydrate (HMB) alone or in combination with 
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 A cause and effect relationship has not been established between the consumption of HMB, 
either alone or in combination with KIC, and faster recovery from muscle fatigue. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-2313, 
EFSA-Q-2008-2314, EFSA-Q-2008-2315, EFSA-Q-2008-2316, EFSA-Q-2008-2317, EFSA-Q-2008-
2318, EFSA-Q-2008-2319, EFSA-Q-2008-2320, EFSA-Q-2008-2321, EFSA-Q-2008-2322, EFSA-Q-
2008-2323, EFSA-Q-2008-2324). The scientific substantiation is based on the information provided 
by the Member States in the consolidated list of Article 13 health claims and references that EFSA 
has received from Member States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent.  
                                                     
6 OJ L12, 18/01/2007 
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
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 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to β-hydroxy β-methylbutyrate monohydrate, either alone or 
in combination with α-ketoisocaproic acid, including conditions of use from similar claims, as 
proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
1576 HMB (B-hydroxy B-
methylbutyrate 
monohydrate) 
Support exercise 
recovery 
Clarification provided 
Muscle recovery: 
Decreases creatine 
phosphokinase and LDH 
response, showing HMB 
helps prevent exercise-
induced muscle damage. 
HMB helps to enhance muscle 
energetics and recuperation. 
HMB helps with muscle energetics 
and recuperation 
  
Conditions of use 
- The product must contain at least 1 gram HMB per serving 
Claim to be used for foods for active individuals 
ID Food or Food constituent Health Relationship Proposed wording 
1577 HMB (B-hydroxy B-
methylbutyrate 
monohydrate) 
Minimize muscle protein 
breakdown 
HMB helps to reduce muscle protein 
breakdown following exercise 
Ingredient clinically shown to support 
protection of muscles from 
breakdown following exercise 
HMB helps to reduce exercise-
induced muscle tissue breakdown. 
Conditions of use 
- The product must contain at least 1 gram HMB per serving 
Claim to be used for foods for active individuals 
ID Food or Food constituent Health Relationship Proposed wording 
1578 HMB (B- hydroxy B- 
methylbutyrate 
monohydrate) 
Increasing strength HMB supports strength 
HMB has been shown to 
increase strength. 
HMB has the ability to enhance 
muscular strength 
Ingredient clinically shown to help 
boost strength 
Boost muscular strength 
Conditions of use 
- The product must contain at least 1 gram HMB per serving 
Claim to be used for foods for active individuals 
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ID Food or Food constituent Health Relationship Proposed wording 
1579 HMB (B-hydroxy B-
methylbutyrate 
monohydrate) 
Increasing Mass Supplementing with HMB may help 
improve body composition 
HMB supports maintenance of lean 
muscle mass 
With proper diet and exercise, HMB 
can help support an increase in fat 
free mass. 
HMB has been shown to increase 
lean muscle mass 
Conditions of use 
- The product must contain at least 1 gram HMB per serving 
Claim to be used for foods for active individuals 
ID Food or Food constituent Health Relationship Proposed wording 
1580 HMB (B-hydroxy B- 
methylbutyrate 
monohydrate) 
Increasing exercise 
lactate threshold and 
VO2 peak 
HMB may help increase the onset of 
blood lactate accumulation and VO2 
peak. 
Conditions of use 
- The product must contain at least 1 gram HMB per serving 
Claim to be used for foods for active individuals 
ID Food or Food constituent Health Relationship Proposed wording 
1581 HMB HMB and aerobic 
metabolism 
Clarification provided 
HMB increases VO2 
max to a greater extent 
than training alone when 
used in conjunction with 
a cardiovascular training 
programme 
HMB supplementation aids aerobic 
metabolism in endurance athletes, 
such as cyclists and runners 
Conditions of use 
- Minimum of 3g per day for 2 weeks (3) 
ID Food or Food constituent Health Relationship Proposed wording 
1582 HMB HMB and lean body 
mass 
HMB can increase gains in lean body 
mass during resistance training 
Conditions of use 
- Minimum of 3g HMB per day for 2 weeks combined with resistance training (10) 
ID Food or Food constituent Health Relationship Proposed wording 
1583 HMB HMB and training 
adaptations 
HMB can improve body adaptation to 
intense training 
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Clarification provided 
Body adaptation to 
training: 
Increase lean body mass 
and muscle strength 
during a weight-training 
program. 
Conditions of use 
- Minimum of 1.5g per day 2 weeks (10) 
ID Food or Food constituent Health Relationship Proposed wording 
1584 HMB and HMB/KIC 
combinations 
HMB and exercise 
induced muscle 
breakdown 
HMB supplementation can reduce 
muscle breakdown after intense 
training.  
HMB reduces the loss of muscle 
proteins after intense training 
Conditions of use 
- Minimum of 3g per day HMB and 0.3g KIC daily for 2 weeks (1) 
ID Food or Food constituent Health Relationship Proposed wording 
1585 HMB and 
HMB/KIC combinations 
HMB and muscle 
recovery after training 
HMB supplementation supports 
muscle recovery after training 
Conditions of use 
- Minimum of 3g per day HMB and 0.3g KIC daily for 2 weeks (1) 
ID Food or Food constituent Health Relationship Proposed wording 
1586 HMB and 
HMB/KIC combinations 
HMB and normal 
muscle repair 
HMB supplementation maintains 
normal muscle repair after training 
Conditions of use 
- Minimum of 3g per day HMB and 0.3g KIC daily for 2 weeks (1) 
ID Food or Food constituent Health Relationship Proposed wording 
1587 HMB and 
HMB/KIC combinations 
HMB and changes in 
muscle strength during 
training 
HMB increases muscle strength when 
taken during a resistance training 
program. 
Conditions of use 
- Minimum of 3g per day HMB and 0.3g KIC daily for 2 weeks (1) taken in conjunction with 
resistance training. 
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α-ketoisocaproic acid (KIC) related health claims 
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GLOSSARY AND ABBREVIATIONS 
BIA  Bioelectrical impedance analysis  
CK  Creatine kinase 
DOMS  Delayed onset muscle soreness 
DXA  Dual-energy x-ray absorptiometry 
HMB  β-hydroxy β-methylbutyric acid 
KIC  α-ketoisocaproic acid 
LDH   Lactate dehydrogenase 
RCT  Randomised controlled trial 
RM  Repetition maximum 
ROM   Range of motion 
TOBEC Total body electrical conductivity 
 
